Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors

Published version of a preprint

Abstract

We evaluated the safety, pharmacokinetic profile, pharmacodynamic effects, and antitumor activity of abemaciclib, an orally bioavailable inhibitor of cyclin-dependent kinases (CDK) 4 and 6, in a multicenter study including phase I dose escalation followed by tumor-specific cohorts for breast cancer, non–small cell lung cancer (NSCLC), glioblastoma, melanoma, and colorectal cancer. A total of 225 patients were enrolled: 33 in dose escalation and 192 in tumor-specific cohorts. Dose-limiting toxicity was grade 3 fatigue. The maximum tolerated dose was 200 mg every 12 hours. The most common possibly related treatment-emergent adverse events involved fatigue and the gastrointestinal, renal, or hematopoietic systems. Plasma concentrations increased with dose, and pharmacodynamic effects were observed in proliferating keratinocytes and tumors. Radiographic responses were achieved in previously treated patients with breast cancer, NSCLC, and melanoma. For hormone receptor–positive breast cancer, the overall response rate was 31%; moreover, 61% of patients achieved either response or stable disease lasting ≥6 months. Significance: Abemaciclib represents the first selective inhibitor of CDK4 and CDK6 with a safety profile allowing continuous dosing to achieve sustained target inhibition. This first-in-human experience demonstrates single-agent activity for patients with advanced breast cancer, NSCLC, and other solid tumors. Cancer Discov; 6(7); 740–53. ©2016 AACR. See related commentary by Lim et al., p. 697. This article is highlighted in the In This Issue feature, p. 681

Overview

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-16-0095

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 48 references

Cited by

See all 743

Metadata

Authors
Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Hilton, J. F., Nasir, A., Beckmann, R. P., Schade, A. E., Fulford, A. D., Nguyen, T. S., Martinez, R., Kulanthaivel, P., Li, L. Q., Frenzel, M., Cronier, D. M., Chan, E. M., Flaherty, K. T., Wen, P. Y., & Shapiro, G. I.
Affiliations
  • South Texas Accelerated Research Therapeutics (US)
  • University of California, Los Angeles (US)
  • Dana-Farber Cancer Institute (US)
  • Eli Lilly (United States) (US)
  • 4Eli Lilly and Company, Indianapolis, Indiana.
  • Massachusetts General Hospital (US)
Corresponding author
Patnaik, Amita
Venue
Cancer Discovery
Published
2016-06-30
Volume
6
Issue
7
Pages
740-753
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2402797587
Cited by
743
References
48
Citations by year
2026: 42 · 2025: 76 · 2024: 45 · 2023: 80 · 2022: 78 · 2021: 100 · 2020: 91 · 2019: 67 · 2018: 79 · 2017: 73 · 2016: 12
FWCI
68.86
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Discovery (publishedVersion)
  • PubMed (publishedVersion)
Funders
Eli Lilly and Company
Topics
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Keywords
abemaciclib, CDK4/6 inhibitors, cyclin-dependent kinases, breast cancer, non-small cell lung cancer, melanoma, glioblastoma, colorectal cancer, solid tumors, pharmacokinetics, pharmacodynamics, dose-limiting toxicity, fatigue, hormone receptor-positive breast cancer, anticancer activity, monotherapy
MeSH terms
Aminopyridines, Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Benzimidazoles, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Disease Models, Animal, Female, Humans, Lung Neoplasms, Male, Neoplasm Metastasis, Neoplasm Staging, Neoplasms, Tomography, X-Ray Computed, Treatment Outcome, Drug Monitoring, Xenograft Model Antitumor Assays, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors. https://app.cochat.ai/papers/10.1158/2159-8290.cd-16-0095
The paper
Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Hilton, J. F., Nasir, A., Beckmann, R. P., Schade, A. E., Fulford, A. D., Nguyen, T. S., Martinez, R., Kulanthaivel, P., Li, L. Q., Frenzel, M., . . . Shapiro, G. I. (2016). Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-16-0095

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.